{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:19:03Z","timestamp":1788437943133,"version":"build-2803163510"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Fixed drug eruptions (FDE) are drug-induced skin reactions that repeatedly occur at the same anatomical site. The skin lesions are usually clear hyperpigmented patches that may develop into blisters. The skin response involves type IV delayed hypersensitivity reactions and is caused by drug-specific memory CD8 T-cells located at the affected skin site. Levocetirizine, an H1-selective second-generation piperazine antihistamine, has a good safety profile and is used to treat the skin reactions. Its nonprescription availability leads to self-medication and unrecognised adverse drug reactions (ADR). FDE due to levocetirizine, as well as with cetirizine, is less common in the literature. This case was reported to our ADR Monitoring Center and causality was assessed as probable and preventable. This case shows that antihistamines such as levocetirizine can trigger FDE in susceptible individuals. Improving clinical awareness through robust Pharmacovigilance activities, educating patients about triggers, and discouraging self-medication are crucial for preventing recurrence.<\/jats:p>","DOI":"10.4103\/ijp.ijp_276_26","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:01:03Z","timestamp":1788354063000},"page":"602-604","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Levocetirizine-induced paradoxical fixed drug eruption: A case report with causality assessment"],"prefix":"10.4103","volume":"58","author":[{"given":"Ambili","family":"Remesh","sequence":"first","affiliation":[{"name":"Department of Pharmacology, SUTAMS, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi S.","family":"Lekshmi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SUTAMS, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramaniam","family":"Reshmi","sequence":"additional","affiliation":[{"name":"Department of Dermatology SUTAMS, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"R1-20260903","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0019-5154.39732","article-title":"Adverse cutaneous drug reaction","volume":"53","author":"Nayak","year":"2008","journal-title":"Indian J Dermatol"},{"key":"R2-20260903","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.clinthera.2009.08.015","article-title":"Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children","volume":"31","author":"Singh-Franco","year":"2009","journal-title":"Clin Ther"},{"key":"R4-20260903","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/0976-500X.184778","article-title":"Fixed drug eruption due to levocetirizine","volume":"7","author":"Jhaj","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"key":"R6-20260903","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R7-20260903","first-page":"2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"R8-20260903","first-page":"538","article-title":"Focusing on the preventability of adverse drug reactions","volume":"27","author":"Schumock","year":"1992","journal-title":"Hosp Pharm"},{"key":"R9-20260903","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13256-018-1801-1","article-title":"Ivermectin-induced fixed drug eruption in an elderly cameroonian: A case report","volume":"12","author":"Ngwasiri","year":"2018","journal-title":"J Med Case Rep"},{"key":"R10-20260903","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000513469","article-title":"Severe generalized bullous fixed drug eruption treated with cyclosporine: A case report and literature review","volume":"13","author":"Barootes","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"R11-20260903","doi-asserted-by":"crossref","first-page":"e71417","DOI":"10.1002\/ccr3.71417","article-title":"Generalized bullous fixed drug eruption secondary to levocetirizine: A lesson learned!","volume":"13","author":"Mathur","year":"2025","journal-title":"Clin Case Rep"},{"key":"R12-20260903","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/cod.14270","article-title":"A case of fixed drug eruption from cetirizine with cross-reaction to levocetirizine and hydroxyzine","volume":"88","author":"Pereira","year":"2023","journal-title":"Contact Dermatitis"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_276_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:03:57Z","timestamp":1788437037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_276_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_276_26","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}